Sugi Predict

Sugi Predict / Compounds / SCHEMBL3870080

SCHEMBL3870080

SCHEMBL3870080

c1ccc(C2CNCC2c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 8/20 0.55
▸ KDM1A O60341 7/20 0.55
▸ MAOB P27338 9/20 0.50
▸ CYP2C19 P33261 4/20 0.50
▸ CYP2B6 P20813 3/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ TAAR1 Q96RJ0 2/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ HTR1A P08908 1/20 0.50
▸ ADRA2A P08913 1/20 0.50
▸ CYP2A6 P11509 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3870077 1.00 MAOA (0.55) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL8660684 1.00 MAOA (0.55) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL31478255 0.87 SLC6A3 (0.57) MAOAKDM1AMAOBSLC6A2SLC6A3
SCHEMBL6438894 0.84 KDM1A (0.54) MAOAKDM1AMAOBADRA2ASLC6A2
SCHEMBL13484227 0.84 MAOA (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL17948233 0.84 MAOA (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL15084368 0.84 MAOA (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL348725 0.84 KDM1A (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL3926813 0.84 KDM1A (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL17172483 0.84 KDM1A (0.47) MAOAKDM1AMAOBCYP2C19CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116546990-B CD73 inhibitor and pharmaceutical application thereof RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) 2026-05-26 — — CN disclosed
CN-114539340-B CD73 inhibitor and pharmaceutical application thereof 润佳（苏州）医药科技有限公司 2024-06-07 — — CN disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
EP-4251633-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-10-04 — — EP disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
CN-116546990-A CD73 inhibitor and pharmaceutical application thereof 润佳（苏州）医药科技有限公司 2023-08-04 — — CN disclosed
CN-114539340-A CD73 inhibitor and pharmaceutical application thereof 润佳（苏州）医药科技有限公司 2022-05-27 — — CN disclosed
US-10954215-B2 Compounds as modulators of ROR gamma BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-03-23 — — US disclosed
EP-3555065-B1 COMPOUNDS AS MODULATORS OF ROR GAMMA BOEHRINGER INGELHEIM INT (DE) 2021-02-24 — — EP disclosed
US-20200071298-A1 COMPOUNDS AS MODULATORS OF ROR GAMMA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-03-05 — — US disclosed
WO-2018111803-A1 COMPOUNDS AS MODULATORS OF ROR GAMMA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-06-21 — — WO disclosed
EP-1845078-B1 PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR TAKASAGO PERFUMERY CO LTD (JP) 2017-06-07 — — EP disclosed
US-7479574-B2 Method of producing macrocyclic ketone, and intermediate thereof TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-01-20 — — US disclosed
US-20070287870-A1 Method of Producing Macrocyclic Ketone, and Intermediate Thereof TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-12-13 — — US disclosed
EP-1845078-A1 PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR Takasago International Corporation (JP) 2007-10-17 — — EP disclosed
US-4443616-A Production of 3-pyrrolin-2-ones THE PURDUE FREDERICK COMPANY (US) 1984-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954215-B2 Compounds as modulators of ROR gamma RORB, RORC, RORA MAOA 3804/4885KDM1A 1955/4885MAOB 3292/4885
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 MAOA 161/4885KDM1A 1802/4885MAOB 205/4885
US-20070287870-A1 Method of Producing Macrocyclic Ketone, and Intermediate Thereof MSMO1, CYP17A1, DNMT1 MAOA 326/4885KDM1A 558/4885MAOB 232/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 MAOA 161/4885KDM1A 1802/4885MAOB 205/4885
US-20200071298-A1 COMPOUNDS AS MODULATORS OF ROR GAMMA RORC, RORB, RORA MAOA 4143/4885KDM1A 1715/4885MAOB 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.